Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Articles

Page Path
HOME > Cancer Res Treat > Volume 44(3); 2012 > Article
Review Article Epithelial Mesenchymal Transition in Drug Resistance and Metastasis of Lung Cancer
Fariz Nurwidya, MD, Fumiyuki Takahashi, MD, PhD, Akiko Murakami, MD, Kazuhisa Takahashi, MD, PhD
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2012;44(3):151-156.
DOI: https://doi.org/10.4143/crt.2012.44.3.151
Published online: September 30, 2012

Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan.

Correspondence: Fariz Nurwidya, MD. Department of Respiratory Medicine, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Tel: 81-80-3690-2529, Fax: 81-3-5802-1617, fariz@juntendo.ac.jp
• Received: March 1, 2012   • Accepted: April 3, 2012

Copyright © 2012 by the Korean Cancer Association

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 16,180 Views
  • 189 Download
  • 131 Crossref
  • 150 Scopus
next
Full Article

Download PDF Download PDF

  • Among all types of cancer, incidence of lung cancer remains the highest with regard to cancer-related mortality. Problems contributing to recurrence of the disease include metastasis and drug resistance. Mounting evidence has demonstrated involvement of epithelial mesenchymal transition (EMT) in cancer progression. EMT is a critical mechanism ensuring tissue remodeling during morphogenesis of multicellular organisms. Therefore, understanding of the biology of this process for identification of potential EMT-targeted therapeutic strategies for the benefit cancer patients is necessary. This review describes recent evidence of EMT involvement in drug resistance and metastasis of cancers, with an emphasis on lung cancer.
  • Key words: Epithelial-mesenchymal transition, Drug resistance, Neoplasm metastasis, Lung neoplasms
In 2008, lung cancer was reported as the most commonly diagnosed cancer as well as the leading cause of cancer death worldwide in males; among females, it was the fourth most commonly diagnosed cancer and the second leading cause of cancer death [1]. When treated with the most active combination of conventional chemotherapeutic agents, the median period of survival for patients with metastatic non-small cell lung cancer (NSCLC) is eight to 10 months [2]. Failure of treatment is attributed to metastasis and recurrence [3].
Some patients exhibit intrinsic resistance to chemotherapy, while other patients, although initially sensitive to chemotherapy, eventually develop acquired resistance, even after combination therapy. Indeed, metastasis and therapeutic resistance have been reported as the major causes of failure of cancer treatment [3]. To circumvent this situation, a new class of drugs that specifically target certain molecular pathways leading to cancer phenotypes is under development [4]. Small molecules that specifically inhibit the tyrosine kinase (tyrosine kinase inhibitors [TKI]) activity of epidermal growth factor receptor (EGFR), such as gefitinib and erlotinib, were the first drugs to become clinically available for treatment of patients with NSCLC [4]. However, despite the efficacy of these drugs in patients with activating mutations, development of acquired resistance in these targeted therapies seems inevitable [5]. Results of multiple prospective trials have shown a response rate of 70% to 75% to TKIs for patients with tumors harboring EGFR mutations [6]. However, this finding indicates that another 25% to 30% of patients have intrinsic resistance to EGFR-TKIs, even though their tumors harbor activating mutations in EGFR. In addition, almost without exception, even patients who show a dramatic response to initial treatment also develop acquired resistance to EGFR-TKI after varying periods of time [7]. Failure of treatment may lead to metastasis of lung cancer. Among organ targets, brain metastasis is a frequent complication of lung cancer and is associated with significant morbidity and mortality [8].
Association of resistance to gefitinib and erlotinib in NSCLC cell lines with epithelial mesenchymal transition (EMT) has been reported [9]. Recently acquired evidence now indicates that EMT of tumor cells not only causes drug resistance, but also increases metastasis [10]. Therefore, in order to pursue possible EMT-inhibiting therapy, understanding of the biology of EMT in cancer is necessary. Findings from Pubmed analysis of EMT and cancer have demonstrated an exponential increase in the number of papers and reviews published under these terms in the last few years [11]. This review describes recent evidence of EMT involvement in drug resistance and metastasis of cancers, with an emphasis on lung cancer.
An epithelium is a collection of cells forming a relatively thin sheet or layer due to mutual and extensive lateral adherence of constituent cells by cell-to-cell junctions [12]. The layer is polarized, with the two sides showing non-identical properties, so that the sides can be defined as, say, inside or outside, or, more precisely, apical and basal [12].
Conversely, mesenchymal cells generally do not exhibit either regimented structure or tight intracellular adhesion [13]. Mesenchymal cells form structures that are irregular in shape, without uniformity in composition or density. Adhesions between mesenchymal cells are not as strong as those of their epithelial counterparts, which allows for increased migratory capacity [13].
The term EMT refers to a complex molecular and cellular program by which epithelial cells shed their differentiated characteristics, including cell-cell adhesion, planar and apical-basal polarity, and lack of motility, and instead acquire mesenchymal features, including motility, invasiveness, and a heightened resistance to apoptosis [14]. The EMT program plays an important role during morphogenesis of multicellular organisms. For example, during gastrulation, epithelial cells located in the primitive streak undergo EMT followed by ingression and migration to a new location where they form endodermal and mesodermal embryonic tissues [15].
However, induction of EMT can compromise the mechanical and physiological integrity of the tissue, and the consequences of inappropriate induction of this process can be disastrous. This can occur in cases of chronic inflammation, which can stimulate fibrosis, a condition in which excess EMT compromises tissue integrity and organ function, or when EMT is acquired by tumor cells [16].
Classification of EMTs into three different biological subtypes based on the biological context in which they occur has been proposed. Kalluri and Weinberg [17] proposed the term 'type 1' EMT. These EMTs, which are associated with implantation, embryo formation, and organ development, are organized for generation of diverse cell types that share common mesenchymal phenotypes. This class of EMTs does not cause fibrosis, nor does it induce an invasive phenotype resulting in systemic spread via the circulation. The type 2 EMT is associated with wound healing, tissue regeneration, and organ fibrosis [17]. In type 2 EMTs, the program begins as part of a repair-associated event that normally results in generation of fibroblasts and other related cells for reconstruction of tissues following trauma and inflammatory injury. However, in contrast to type 1 EMTs, type 2 EMTs are associated with inflammation, and cease once inflammation is attenuated, as observed during wound healing and tissue regeneration. Type 3 EMTs occur in neoplastic cells that have previously undergone genetic and epigenetic changes, specifically in genes that favor clonal outgrowth and development of localized tumors [17].
E-cadherin is a cell-cell adhesion molecule that participates in homotypic, calcium-dependent interactions for formation of epithelial adherent junctions and sequestration of β-catenin [18]. Several transcription factors have been implicated in transcriptional repression of E-cadherin. EMT inducers can be classified according to: 1) their effects on the E-cadherin promoter, and 2) source of the stimuli. Based on their effects on the E-cadherin promoter, there are two types of EMT inducer. The first type, such as Snail, ZEB, E47, and KLF8 factors, represses the activity of the E-cadherin promoter [19], and the second type, such as Twist, Goosecoid, E2.2, and FoxC2, is involved in indirect repression of E-cadherin transcription [19].
Regardless of the mechanism, E-cadherin repressors function as full EMT inducers in many cellular contexts, regulating expression of a variety of genes involved in repression of the epithelial character and promotion of the mesenchymal state [19]. Meanwhile, based on the source of stimuli, EMT inducers can be classified into two groups: external stimuli (that is microenvironment) and internal stimuli.
1. External stimuli and transcriptional factors
The tumor microenvironment, which is composed of extracellular matrix, cells, and soluble factors, plays an important role in EMT induction and further in metastasis [20]. Several stromal cell subtypes, including macrophages, contribute to tumor progression through induction of EMT at the invasive front, a mechanism also linked to metastasis [21].
Tissue-culture studies have been instrumental in defining molecular regulation of EMT. Findings from these studies have demonstrated that signalling pathways for induction of EMT have many common endpoints, including down-regulation of E-cadherin expression and expression of EMT-associated genes; in addition, triggering of EMT by several extracellular activators, and existence of extensive crosstalk between signalling pathways involved in activation and repression of EMT have also been reported [22].
Several tyrosine kinase receptors, including mesenchymal-epithelial transition (MET), fibroblast growth factor, insulin growth factor, epithelial growth factor family members, and, more recently, platelet derived growth factor, also play critical roles in regulation of EMT-like morphogenetic events that occur during development [23].
The three members of the Snail family, known as Snail (Snail1), Slug (Snail2), and Smuc (Snail3), encode zinc-finger type transcription factors [18]. The carboxyl-terminal domain, containing four to six C2H2-type zinc fingers, is the most conserved feature of the Snail family of proteins [18]. Evidence has indicated a fundamental role of Snail in EMT through its suppression of E-cadherin [24]. Up-regulation and nuclear accumulation of Snail have shown correlation with the EMT program in tumor tissues [25]. In addition, Kudo-Saito et al. [26] reported on acceleration of cancer metastasis by Snail-induced EMT through enhanced invasion.
The transcriptional repressor zinc-finger E-box binding homeobox 1 (ZEB1) is a crucial inducer of EMT in various human tumours, and was recently shown to promote invasion and metastasis of tumour cells [27]. ZEB1 promotes EMT through repression of genes such as E-cadherin, which is involved in maintenance of the epithelial phenotype and activation of those required for transformation to the mesenchymal phenotype [28]. Repression of multiple key determinants of epithelial differentiation and cell-cell adhesion, including the cell polarity genes Crumbs3, HUGL2, and Pals1-associated tight junction protein, by ZEB1 has also been demonstrated [29]. Results of reporter assays showed an association of ZEB1 with endogenous promoters in vivo, as well as strong repression of promoter activities [29]. Early evidence from studies conducted using mouse models, as well as a wide range of primary human carcinomas, demonstrated induction of an EMT by ZEB proteins, linking their expression with increased aggressiveness and metastasis [30].
The increase in expression of Bmi-1 was accompanied by down-regulation of E-cadherin expression and up-regulation of vimentin expression in lung squamous cell carcinoma tissues [31]. Over-expression of Bmi-1 has been reported to increase the motility and invasive properties of immortalized human mammary epithelial cells (HMLEs), which is concurrent with increased expression of mesenchymal markers, decreased expression of epithelial markers, stabilization of Snail, and dysregulation of the Akt/GSK3b pathway [32]. Silencing of endogenous Bmi-1 expression has been shown to result in reversal of EMT and reduction of motility [33]. Some data have suggested that Bmi-1 expression may be regulated by Twist1 [34].
2. Internal stimuli
The prominent idea is that, although some factors, such as transforming growth factor-β (TGF-β), could possibly trigger EMT, accumulation of particular gene mutations would be required in order to unlock or maintain the EMT program. Indeed, gene alterations concerning extracellular receptors and/or consequent signal transduction are common in cancer [20]. Pirozzi et al. [35] reported that treatment with TGF-β1 induced morphologic changes in NSCLC cell lines, characterized by loss of epithelial morphology assuming a fibroblast-like appearance. Treatment with TGF-β1 has also been shown to promote a shift from epithelial to mesenchymal phenotype [35]. Induced autocrine expression of TGF-β resulted in changes in markers and phenotype that were consistent with EMT, a modest effect on growth rate, and a shift to a more invasive phenotype [36]. In addition, several other mechanisms having the capacity to suppress E-cadherin expression, including somatic mutations, promoter hypermethylation, and histone deacetylation, have also been described [30].
EMT may well play a role in determining sensitivity to EGFR-TKI. Thomson et al. [37] reported that human NSCLC lines containing wild-type EGFR, grown both in culture and as xenografts, display a range of sensitivities to EGFR inhibition, which is dependent on the degree to which they have undergone EMT. NSCLC lines expressing the epithelial cell junction protein E-cadherin showed greater sensitivity to EGFR inhibition in vitro and in xenografts. By contrast, NSCLC lines that had undergone EMT, expressing vimentin and/or fibronectin, were insensitive to the growth inhibitory effects of EGFR kinase inhibition in vitro and in xenografts.
In another study by Xie et al. [38], highly up-regulated expression of Notch-1 was observed in gefitinib-resistant PC9/AB2 lung cancer cells. Promotion of the EMT phenotype by the Notch-1 receptor intracellular domain (N1IC), the activated form of the Notch-1 receptor, was observed in PC9 cells. Silencing of Notch-1 using siRNA resulted in reversal of the EMT phenotype and restored sensitivity to gefitinib in PC9/AB2 cells. In addition, involvement of Notch-1 reduction in inhibition of anoikis, as well as colony-formation activity of PC9/AB2 cells, was also observed. Taken together, these results provide strong molecular evidence that gefitinib-acquired resistance in lung cancer cells undergoing EMT occurs through activation of Notch-1 signaling.
Using cancer specimens, Uramoto et al. [39] investigated the association between EMT status and acquired resistance. Immunohistochemical staining was performed for analysis of protein expression of epithelial and mesenchymal markers in tumour samples from patients with lung adenocarcinoma. All patients showed positive expression of epithelial markers in sensitive tumours. Findings from the study suggest that epithelial markers tended toward a slight decrease in resistance, compared with sensitive tumours. By contrast, mesenchymal markers tended toward a slight increase; however, the differences were not statistically significant [39].
However, according to findings from another study, continuous exposure of A549, a lung adenocarcinoma cell line, to gefitinib also resulted in induction of EMT [40]. Rho et al. [40] reported on use of a gefitinib-resistant subline (A549/GR) derived from the parental A549 cell line through chronic and repeated exposure to gefitinib. Phenotypic changes, including a spindle-cell shape and increased pseudopodia formation, suggesting EMT, were observed in A549/GR cells. These changes were accompanied by a decrease of E-cadherin and an increase of vimentin, a mesenchymal marker. In addition, A549/GR cells showed ~7.7-fold greater resistance to gefitinib and demonstrated cross-resistance against other EGFR-TKI, including CL-387,758, erlotinib, and ZD6478.
Metastasis occurs when genetically unstable cancer cells adapt to a tissue microenvironment that is distant from the primary tumor [41]. Origins of invasive and metastatic phenotypes of carcinoma cells have been the subject of intensive investigation. Tumor metastasis involves a sequential series of processes that promote and regulate the escape of migratory cancer cells for generation of metastatic lesions at distant sites [42]. Mounting evidence has suggested an association of metastasis of primary epithelial tumor cells, the primary cause of death in cancer patients, with loss of E-cadherin-mediated cell-cell contacts and gain of a mesenchymal phenotype, potentially facilitating cellular motility and invasion [43].
Molecular technologies, including DNA, antibody, and proteomic arrays, and short-hairpin RNA libraries, have been used for identification of multiple molecules that contribute to the metastatic process, including growth factors, cytokines and chemokines, pro-angiogenic factors, extracellular matrix-remodeling molecules, and, most recently, transcription factors that may regulate cellular changes during tumor invasion-metastasis [44]. One view proposes that metastatic traits are acquired through exposure of epithelial cancer cells to paracrine signals received from mesenchymal cell types within the tumour-associated stroma [45]. Metastatic colonization involves lodgment or adherence of cancer cells in the microvasculature and subsequent migration of those cells across the endothelium into a secondary organ site [46].
Cancer stem cells have the capacity for division and expansion of the cancer stem cell pool and for differentiation into the heterogeneous non-tumorigenic cancer cell types that, in most cases, appear to constitute the bulk of cancer cells within the tumor [47].
A four-week period of exposure of immortalized human bronchial epithelial cells to tobacco carcinogens has been shown to induce a persistent, irreversible, and multifaceted dedifferentiation program marked by EMT and the emergence of stem cell-like properties [48].
Induction of EMT in immortalized HMLEs has been reported to result in acquisition of mesenchymal traits, as well as expression of stem-cell markers [49]. In addition, these cells have an increased ability to form mammospheres, a property associated with mammary epithelial stem cells [49,50]. Cancer cells in EMT, that is, EMT cells, share many propertieswith the classical so-called 'cancer stem cells (CSCs).' In fact, there are many indications that CSC-tumor propagating cells present characteristics of EMT cells, and, conversely, that EMT cells acquire properties of the so-called 'CSCs' (for example, markers CD44+/CD24+/-, dormancy, etc.) and that these are reversible [51].
Ding et al. [52] investigated the question of whether CSC markers are associated with EMT. For Capan1M9, a highly migratory cell subclone established from human pancreatic cancer cell line Capan-1, expression, migration, and invasion of CD133 were greater than that for the parent cells. Up-regulation of EMT-related transcription factors Slug and Snail, as well as a substantial increase in N-cadherin and fibronectin, were observed in Capan1M9 cells. By contrast, occludin and desmoplakin were suppressed. Knockdown of endogenous CD133 in Capan1M9 cells led to suppression of Slug and reduction of migration and invasion. Taken together, CD133 has an important role in migration and invasion through facilitation of EMT in pancreatic cancer cells.
On the basis of their studies, Brabletz et al. [53] postulated that EMT and stem-cell properties are combined in invasive cancer cells-which often co-express EMT and stem-cell markers-and proposed the concept of the 'migrating cancer stem cell.' This concept links two features: 1) classical EMT-associated features that support tumor cell motility and dissemination, and allow for survival of cells under the stressful conditions of a new environment; and 2) the associated stem-cell properties, including prevention of senescence, allowing for unlimited reconstitution of the tumor at a distant site, leading ultimately to metastasis [53].
Soltermann et al. [54] investigated the prognostic significance of the EMT indicator proteins periostin and vimentin in comparison with versican, a putative indicator of the opposite mechanism, MET, and the desmoplasia proteins collagen and elastin in NSCLC. Tumors of 533 patients with surgically resected NSCLC were used for analysis of stromal and epithelial protein expression by immunohistochemistry. High expression of versican in either stroma or epithelia as well as of stromal collagen showed fewer but concordant associations with advanced tumor and periostin, respectively. High expression of elastin showed an opposite associationwith less advanced disease.
Loss of epithelial proteins and/or acquisition of mesenchymal proteins are associated with poorly differentiated histology, advanced stage, and poor outcome [55]. However, findings from the study also revealed that EMT status in the primary tumor is not predictive of postoperative recurrence or disease-free survival in patients with lung cancer [56].
EMT has been established as a mechanism that confers tumor cells with abilities essential for drug resistance, metastasis, and acquired-tumor stem cell traits. Therefore, inhibition of EMT can be a critical therapeutic strategy for prevention of tumor progression. Forced expression of miR-200 resulted in abrogation of the capacity of lung cancer cell lines to undergo EMT, invade, and metastasize, and conferred transcriptional features of metastasis-incompetent tumor cells [57]. Restoration of E-cadherin-mediated cell adhesion is another means by which prevention of EMT in cancer might be possible [58]. Inhibition of EMT by NPI-0052, a protesome inhibitor, via inhibition of nuclear factor-κB and Snail has also been demonstrated [59], whereas over-expression of FOXA2 resulted in reduced invasion and suppression of TGF-β1-induced EMT [60]. Meanwhile, activation of peroxisome proliferator-activated receptor-g was reported to inhibit TGF-β-induced EMT in lung cancer cells and prevent metastasis by antagonizing Smad3 function [61].
Research on the role of EMT in cancer progression, in terms of drug resistance and metastasis, is currently in a very active phase, with several significant publications every year. At this pace, it seems likely that we will soon have a better understanding of how to inhibit this crucial process in order to prevent cancer progression.
Given the role of EMT in promoting chemoresistance, invasion, and stem cell-like properties, specific targeting of EMT could potentially serve to decrease metastasis and overcome drug resistance; however, significant additional work is needed in order to translate these findings into meaningful therapies.

Conflict of interest relevant to this article was not reported.

  • 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. PMID: 21296855ArticlePubMed
  • 2. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007;18:317–323. PMID: 17079694ArticlePubMed
  • 3. Xiao D, He J. Epithelial mesenchymal transition and lung cancer. J Thorac Dis. 2010;2:154–159. PMID: 22263037ArticlePubMedPMC
  • 4. Mitsudomi T. Advances in target therapy for lung cancer. Jpn J Clin Oncol. 2010;40:101–106. PMID: 20031962ArticlePubMed
  • 5. Giaccone G. EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer. Nat Clin Pract Oncol. 2005;2:296–297. PMID: 16264986ArticlePubMed
  • 6. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98:1817–1824. PMID: 17888036ArticlePubMedPMC
  • 7. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008;68:9479–9487. PMID: 19010923ArticlePubMed
  • 8. Jamal-Hanjani M, Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res. 2012;18:938–944. PMID: 22167408ArticlePubMed
  • 9. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res. 2005;11(24 Pt 1):8686–8698. PMID: 16361555ArticlePubMed
  • 10. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741–4751. PMID: 20531305ArticlePubMedPMC
  • 11. Thompson EW, Williams ED. EMT and MET in carcinoma: clinical observations, regulatory pathways and new models. Clin Exp Metastasis. 2008;25:591–592. PMID: 18566898ArticlePubMed
  • 12. Thompson EW, Newgreen DF, Tarin D. Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res. 2005;65:5991–5995. PMID: 16024595ArticlePubMed
  • 13. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172:973–981. PMID: 16567498ArticlePubMedPMC
  • 14. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265–273. PMID: 19262571ArticlePubMed
  • 15. Battula VL, Evans KW, Hollier BG, Shi Y, Marini FC, Ayyanan A, et al. Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells. 2010;28:1435–1445. PMID: 20572012ArticlePubMedPMC
  • 16. Radisky DC. Epithelial-mesenchymal transition. J Cell Sci. 2005;118(Pt 19):4325–4326. PMID: 16179603ArticlePubMed
  • 17. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420–1428. PMID: 19487818ArticlePubMedPMC
  • 18. Shih JY, Yang PC. The EMT regulator slug and lung carcinogenesis. Carcinogenesis. 2011;32:1299–1304. PMID: 21665887ArticlePubMed
  • 19. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–890. PMID: 19945376ArticlePubMed
  • 20. Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 2009;1796:75–90. PMID: 19306912ArticlePubMed
  • 21. Bonde AK, Tischler V, Kumar S, Soltermann A, Schwendener RA. Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors. BMC Cancer. 2012;12:35PMID: 22273460ArticlePubMedPMC
  • 22. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–142. PMID: 16493418ArticlePubMed
  • 23. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14:818–829. PMID: 18539112ArticlePubMed
  • 24. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol. 2004;6:931–940. PMID: 15448698ArticlePubMed
  • 25. Lee MY, Chou CY, Tang MJ, Shen MR. Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation. Clin Cancer Res. 2008;14:4743–4750. PMID: 18676743ArticlePubMed
  • 26. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 2009;15:195–206. PMID: 19249678ArticlePubMed
  • 27. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008;9:582–589. PMID: 18483486ArticlePubMedPMC
  • 28. Hurt EM, Saykally JN, Anose BM, Kalli KR, Sanders MM. Expression of the ZEB1 (deltaEF1) transcription factor in human: additional insights. Mol Cell Biochem. 2008;318:89–99. PMID: 18622689ArticlePubMed
  • 29. Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, et al. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene. 2007;26:6979–6988. PMID: 17486063ArticlePubMedPMC
  • 30. Dasari V, Gallup M, Lemjabbar H, Maltseva I, McNamara N. Epithelial-mesenchymal transition in lung cancer: is tobacco the "smoking gun"? Am J Respir Cell Mol Biol. 2006;35:3–9. PMID: 16484682ArticlePubMed
  • 31. Huang J, Qiu Y, Chen G, Huang L, He J. The relationship between Bmi-1 and the epithelial-mesenchymal transition in lung squamous cell carcinoma. Med Oncol. 2012;29:1606–1613. PMID: 21656027ArticlePubMed
  • 32. Guo BH, Feng Y, Zhang R, Xu LH, Li MZ, Kung HF, et al. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer. 2011;10:10PMID: 21276221ArticlePubMedPMC
  • 33. Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest. 2009;119:3626–3636. PMID: 19884659ArticlePubMedPMC
  • 34. Yang MH, Hsu DS, Wang HW, Wang HJ, Lan HY, Yang WH, et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol. 2010;12:982–992. PMID: 20818389ArticlePubMed
  • 35. Pirozzi G, Tirino V, Camerlingo R, Franco R, La Rocca A, Liguori E, et al. Epithelial to mesenchymal transition by TGFbeta-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS One. 2011;6:e21548PMID: 21738704ArticlePubMedPMC
  • 36. Argast GM, Krueger JS, Thomson S, Sujka-Kwok I, Carey K, Silva S, et al. Inducible expression of TGFbeta, snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model. Clin Exp Metastasis. 2011;28:593–614. PMID: 21643654ArticlePubMed
  • 37. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005;65:9455–9462. PMID: 16230409ArticlePubMed
  • 38. Xie M, Zhang L, He CS, Xu F, Liu JL, Hu ZH, et al. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. J Cell Biochem. 2012;113:1501–1513. PMID: 22173954ArticlePubMed
  • 39. Uramoto H, Iwata T, Onitsuka T, Shimokawa H, Hanagiri T, Oyama T. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res. 2010;30:2513–2517. PMID: 20682976PubMed
  • 40. Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer. 2009;63:219–226. PMID: 18599154ArticlePubMed
  • 41. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127:679–695. PMID: 17110329ArticlePubMed
  • 42. Barr S, Thomson S, Buck E, Russo S, Petti F, Sujka-Kwok I, et al. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis. 2008;25:685–693. PMID: 18236164ArticlePubMedPMC
  • 43. Eastham AM, Spencer H, Soncin F, Ritson S, Merry CL, Stern PL, et al. Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. Cancer Res. 2007;67:11254–11262. PMID: 18056451ArticlePubMed
  • 44. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010;70:5649–5669. PMID: 20610625ArticlePubMedPMC
  • 45. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449:557–563. PMID: 17914389ArticlePubMed
  • 46. Drake JM, Strohbehn G, Bair TB, Moreland JG, Henry MD. ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells. Mol Biol Cell. 2009;20:2207–2217. PMID: 19225155ArticlePubMedPMC
  • 47. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells: perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:9339–9344. PMID: 16990346ArticlePubMed
  • 48. Tellez CS, Juri DE, Do K, Bernauer AM, Thomas CL, Damiani LA, et al. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res. 2011;71:3087–3097. PMID: 21363915ArticlePubMedPMC
  • 49. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–715. PMID: 18485877ArticlePubMedPMC
  • 50. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One. 2008;3:e2888PMID: 18682804ArticlePubMedPMC
  • 51. Floor S, van Staveren WC, Larsimont D, Dumont JE, Maenhaut C. Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene. 2011;30:4609–4621. PMID: 21643013ArticlePubMed
  • 52. Ding Q, Yoshimitsu M, Kuwahata T, Maeda K, Hayashi T, Obara T, et al. Establishment of a highly migratory subclone reveals that CD133 contributes to migration and invasion through epithelial-mesenchymal transition in pancreatic cancer. Hum Cell. 2012;25:1–8. PMID: 22109279ArticlePubMed
  • 53. Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop: a motor of cellular plasticity in development and cancer? EMBO Rep. 2010;11:670–677. PMID: 20706219ArticlePubMedPMC
  • 54. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, et al. Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res. 2008;14:7430–7437. PMID: 19010860ArticlePubMed
  • 55. Kim MA, Lee HS, Lee HE, Kim JH, Yang HK, Kim WH. Prognostic importance of epithelial-mesenchymal transition-related protein expression in gastric carcinoma. Histopathology. 2009;54:442–451. PMID: 19309396ArticlePubMed
  • 56. Chikaishi Y, Uramoto H, Tanaka F. The EMT status in the primary tumor does not predict postoperative recurrence or disease-free survival in lung adenocarcinoma. Anticancer Res. 2011;31:4451–4456. PMID: 22199314PubMed
  • 57. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, et al. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 2009;23:2140–2151. PMID: 19759262ArticlePubMedPMC
  • 58. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–454. PMID: 12189386ArticlePubMed
  • 59. Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene. 2009;28:3573–3585. PMID: 19633685ArticlePubMed
  • 60. Tang Y, Shu G, Yuan X, Jing N, Song J. FOXA2 functions as a suppressor of tumor metastasis by inhibition of epithelial-to-mesenchymal transition in human lung cancers. Cell Res. 2011;21:316–326. PMID: 20820189ArticlePubMedPMC
  • 61. Reka AK, Kurapati H, Narala VR, Bommer G, Chen J, Standiford TJ, et al. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor metastasis by antagonizing Smad3-mediated epithelial-mesenchymal transition. Mol Cancer Ther. 2010;9:3221–3232. PMID: 21159608ArticlePubMedPMC

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  
    • SERPING1 Reduces Cell Migration via ERK‐MMP2‐MMP‐9 Cascade in Sorafenib‐ Resistant Hepatocellular Carcinoma
      Ching‐Chuan Hsieh, Yuh‐Harn Wu, Yi‐Li Chen, Chun‐I Wang, Chao‐Jen Li, I‐Hsiu Liu, Chen‐Wei Chou, Yang‐Hsiang Lin, Po‐Shuan Huang, Te‐Chia Huang, Cheng‐Yi Chen
      Environmental Toxicology.2025; 40(2): 318.     CrossRef
    • Dynamic Multilevel Regulation of EGFR, KRAS, and MYC Oncogenes: Driving Cancer Cell Proliferation Through (Epi)Genetic and Post-Transcriptional/Translational Pathways
      Mario Seres, Katarina Spacayova, Zdena Sulova, Jana Spaldova, Albert Breier, Lucia Pavlikova
      Cancers.2025; 17(2): 248.     CrossRef
    • DRMref: comprehensive reference map of drug resistance mechanisms in human cancer
      Xiaona Liu, Jiahao Yi, Tina Li, Jianguo Wen, Kexin Huang, Jiajia Liu, Grant Wang, Pora Kim, Qianqian Song, Xiaobo Zhou
      Nucleic Acids Research.2024; 52(D1): D1253.     CrossRef
    • Exploring the influence of microgravity on chemotherapeutic drug response in cancer: Unveiling new perspectives
      Preksha Manish Vora, Sudharshan Prabhu
      Journal of Cellular and Molecular Medicine.2024;[Epub]     CrossRef
    • Abemaciclib-induced epithelial-mesenchymal transition mediated by cyclin-dependent kinase 4/6 independent of cell cycle arrest pathway
      Tomoyo Yoshimori, Masashi Kawami, Yuta Kumagai, Sorahito Futatsugi, Ryoko Yumoto, Yasuo Uchida, Mikihisa Takano
      The International Journal of Biochemistry & Cell Biology.2024; 172: 106601.     CrossRef
    • Overcoming AZD9291 Resistance and Metastasis of NSCLC via Ferroptosis and Multitarget Interference by Nanocatalytic Sensitizer Plus AHP‐DRI‐12
      Liting Wang, Hao Fu, Liwei Song, Zhihua Wu, Jian Yu, Qianqian Guo, Chuanrong Chen, Xupeng Yang, Jiali Zhang, Quan Wang, Yourong Duan, Yunhai Yang
      Small.2023;[Epub]     CrossRef
    • Pomiferin targets SERCA, mTOR, and P-gp to induce autophagic cell death in apoptosis-resistant cancer cells, and reverses the MDR phenotype in cisplatin-resistant tumors in vivo
      Yuan-Qing Qu, Lin-Lin Song, Su-Wei Xu, Margaret Sum Yee Yu, Onat Kadioglu, Francesco Michelangeli, Betty Yuen Kwan Law, Thomas Efferth, Christopher Wai-Kei Lam, Vincent Kam Wai Wong
      Pharmacological Research.2023; 191: 106769.     CrossRef
    • Inferring ligand-receptor cellular networks from bulk and spatial transcriptomic datasets with BulkSignalR
      Jean-Philippe Villemin, Laia Bassaganyas, Didier Pourquier, Florence Boissière, Simon Cabello-Aguilar, Evelyne Crapez, Rita Tanos, Emmanuel Cornillot, Andrei Turtoi, Jacques Colinge
      Nucleic Acids Research.2023; 51(10): 4726.     CrossRef
    • RGMb impacts partial epithelial‐mesenchymal transition and BMP2‐Induced ID mRNA expression independent of PD‐L2 in nonsmall cell lung cancer cells
      Sofie Rahbek Dorset, Tina Fuglsang Daugaard, Trine Vilsbøll Larsen, Anders Lade Nielsen
      Cell Biology International.2023; 47(11): 1799.     CrossRef
    • The Impacts and Changes Related to the Cancer Drug Resistance Mechanism
      Prachi Varshney, Vishal Sharma, Devdhar Yadav, Yogesh Kumar, Amit Singh, Naga Rani Kagithala, Pramod Kumar Sharma, Omji Porwal, Neeraj Kumar Fuloria, Pradeep Kumar Sharma, Ashok Kumar Gupta, Koteswara Rao GSN
      Current Drug Metabolism.2023; 24(12): 787.     CrossRef
    • Quercetin Inhibits the Epithelial to Mesenchymal Transition through Suppressing Akt Mediated Nuclear Translocation of β-Catenin in Lung Cancer Cell Line
      Perumal Elumalai, Devaraj Ezhilarasan, Subramanian Raghunandhakumar
      Nutrition and Cancer.2022; 74(5): 1894.     CrossRef
    • Resistance to cisplatin in human lung adenocarcinoma cells: effects on the glycophenotype and epithelial to mesenchymal transition markers
      Leonardo Marques da Fonseca, Vanessa Amil da Silva, Kelli Monteiro da Costa, Jhenifer Santos dos Reis, José Osvaldo Previato, Lucia Mendonça Previato, Leonardo Freire-de-Lima
      Glycoconjugate Journal.2022; 39(2): 247.     CrossRef
    • Study on the mechanism of Cortex Lycii on lung cancer based on network pharmacology combined with experimental validation
      Zhenhui Guo, Heng Yin, Tong Wu, Shaofeng Wu, Lingyun Liu, Lei Zhang, Yanli He, Ren Zhang, Na Liu
      Journal of Ethnopharmacology.2022; 293: 115280.     CrossRef
    • Statistical parametrization of cell cytoskeleton reveals lung cancer cytoskeletal phenotype with partial EMT signature
      Arkaprabha Basu, Manash K. Paul, Mitchel Alioscha-Perez, Anna Grosberg, Hichem Sahli, Steven M. Dubinett, Shimon Weiss
      Communications Biology.2022;[Epub]     CrossRef
    • Fangchinoline targets epithelial–mesenchymal transition process by modulating activation of multiple cell‐signaling pathways
      Young Y. Jung, Arunachalam Chinnathambi, Tahani A. Alahmadi, Sulaiman A. Alharbi, Alan P. Kumar, Gautam Sethi, Kwang S. Ahn
      Journal of Cellular Biochemistry.2022; 123(7): 1222.     CrossRef
    • Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer
      Kuojun Zhang, Kaizhen Wang, Xiangyu Zhang, Zhenlong Qian, Wenbo Zhang, Xiao Zheng, Jiaying Wang, Yin Jiang, Wanheng Zhang, Zhiyu Lu, Haiping Hao, Sheng Jiang
      Journal of Medicinal Chemistry.2022; 65(11): 7746.     CrossRef
    • Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting
      Rahul Rimal, Prachi Desai, Rasika Daware, Aisa Hosseinnejad, Jai Prakash, Twan Lammers, Smriti Singh
      Advanced Drug Delivery Reviews.2022; 189: 114504.     CrossRef
    • Crizotinib attenuates cancer metastasis by inhibiting TGFβ signaling in non-small cell lung cancer cells
      Soonbum Park, Eun A Cho, Jung Nyeo Chun, Da Young Lee, Sanghoon Lee, Mi Yeon Kim, Sang Mun Bae, Su In Jo, So Hee Lee, Hyun Ho Park, Tae Min Kim, Insuk So, Sang-Yeob Kim, Ju-Hong Jeon
      Experimental & Molecular Medicine.2022; 54(8): 1225.     CrossRef
    • The actin cytoskeleton: Morphological changes in pre- and fully developed lung cancer
      Arkaprabha Basu, Manash K. Paul, Shimon Weiss
      Biophysics Reviews.2022;[Epub]     CrossRef
    • Challenges and Opportunities in Cancer Drug Resistance
      Richard A. Ward, Stephen Fawell, Nicolas Floc’h, Vikki Flemington, Darren McKerrecher, Paul D. Smith
      Chemical Reviews.2021; 121(6): 3297.     CrossRef
    • Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I
      Archana Upadhya, Khushwant S. Yadav, Ambikanandan Misra
      Expert Opinion on Drug Delivery.2021; 18(1): 73.     CrossRef
    • Design, Synthesis and Biological Evaluation of New Pyrimidine Derivatives as Anticancer Agents
      Valentina Noemi Madia, Alice Nicolai, Antonella Messore, Alessandro De Leo, Davide Ialongo, Valeria Tudino, Francesco Saccoliti, Daniela De Vita, Luigi Scipione, Marco Artico, Samanta Taurone, Ludovica Taglieri, Roberto Di Santo, Susanna Scarpa, Roberta C
      Molecules.2021; 26(3): 771.     CrossRef
    • Cytoskeletal Dynamics in Epithelial-Mesenchymal Transition: Insights into Therapeutic Targets for Cancer Metastasis
      Arpita Datta, Shuo Deng, Vennila Gopal, Kenneth Chun-Hong Yap, Clarissa Esmeralda Halim, Mun Leng Lye, Mei Shan Ong, Tuan Zea Tan, Gautam Sethi, Shing Chuan Hooi, Alan Prem Kumar, Celestial T. Yap
      Cancers.2021; 13(8): 1882.     CrossRef
    • ARHGAP10 inhibits the epithelial–mesenchymal transition of non-small cell lung cancer by inactivating PI3K/Akt/GSK3β signaling pathway
      Lan-Lan Lin, Fan Yang, Dong-Huan Zhang, Cong Hu, Sheng Yang, Xiang-Qi Chen
      Cancer Cell International.2021;[Epub]     CrossRef
    • Roles and Regulation of Growth differentiation factor-15 in the Immune and tumor microenvironment
      Rathna Silviya Lodi, Bin Yu, Lin Xia, Fang Liu
      Human Immunology.2021; 82(12): 937.     CrossRef
    • Potential function of oxymatrine as a novel suppressor of epithelial-to-mesenchymal transition in lung tumor cells
      Young Yun Jung, Seung Ho Baek, Acharan S. Narula, Ojas A. Namjoshi, Bruce E. Blough, Kwang Seok Ahn
      Life Sciences.2021; 284: 119893.     CrossRef
    • Prognostic value of epithelial‐mesenchymal transition‐inducing transcription factors in head and neck squamous cell carcinoma: A meta‐analysis
      Yuehan Wan, Haichao Liu, Ming Zhang, Zhengxian Huang, Han Zhou, Yue Zhu, Yifan Tao, Nan Xie, Xiqiang Liu, Jinsong Hou, Cheng Wang
      Head & Neck.2020; 42(5): 1067.     CrossRef
    • Fucoidan increased the sensitivity to gefitinib in lung cancer cells correlates with reduction of TGFβ-mediated Slug expression
      Wei-Lun Qiu, Ai-Jung Tseng, Hsien-Yeh Hsu, Wei-Hung Hsu, Zhi-Hu Lin, Wei-Jyun Hua, Tung-Yi Lin
      International Journal of Biological Macromolecules.2020; 153: 796.     CrossRef
    • Precision Management of Advanced Non–Small Cell Lung Cancer
      Ching-Yao Yang, James Chih-Hsin Yang, Pan-Chyr Yang
      Annual Review of Medicine.2020; 71(1): 117.     CrossRef
    • Postpartum breast cancer progression is driven by semaphorin 7a-mediated invasion and survival
      Sarah E. Tarullo, Ryan C. Hill, Kirk C. Hansen, Fariba Behbod, Virginia F. Borges, Andrew C. Nelson, Traci R. Lyons
      Oncogene.2020; 39(13): 2772.     CrossRef
    • Uptake of collagen type I via macropinocytosis cause mTOR activation and anti-cancer drug resistance
      Shota Yamazaki, Yinghan Su, Ami Maruyama, Hideki Makinoshima, Jun Suzuki, Masahiro Tsuboi, Koichi Goto, Atsushi Ochiai, Genichiro Ishii
      Biochemical and Biophysical Research Communications.2020; 526(1): 191.     CrossRef
    • LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers
      Chen Chen, Wei-Ran Liu, Bin Zhang, Lian-Min Zhang, Chen-Guang Li, Chang Liu, Hua Zhang, Yan-Song Huo, Yu-Chen Ma, Peng-Fei Tian, Qi Qi, Jing-Jing Li, Zhe Tang, Zhen-Fa Zhang, Giuseppe Giaccone, Dong-Sheng Yue, Chang-Li Wang
      Cancer Letters.2020; 486: 58.     CrossRef
    • Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo
      Ning Liu, Mingxing Ma, Na Qu, Ruizhe Wang, Hao Chen, Fangzhu Hu, Song Gao, Fengping Shan
      International Immunopharmacology.2020; 86: 106718.     CrossRef
    • Drug resistance in cancer: mechanisms and tackling strategies
      Tanweer Haider, Vikas Pandey, Nagma Banjare, Prem N. Gupta, Vandana Soni
      Pharmacological Reports.2020; 72(5): 1125.     CrossRef
    • Targeting Notch signaling pathway as an effective strategy in overcoming drug resistance in ovarian cancer
      Maryam Akbarzadeh, Shabnam Akbarzadeh, Maryam Majidinia
      Pathology - Research and Practice.2020; 216(11): 153158.     CrossRef
    • MicroRNA-7 targets T-Box 2 to inhibit epithelial-mesenchymal transition and invasiveness in glioblastoma multiforme
      Chih-Ming Pan, Kai-Hsiang Chan, Chao-Hsuan Chen, Chia-Ing Jan, Ming-Chao Liu, Chien-Min Lin, Der-Yang Cho, Wan-Chen Tsai, Yen-Tse Chu, Cheng-Hsin Cheng, Hao-Yu Chuang, Shao-Chih Chiu
      Cancer Letters.2020; 493: 133.     CrossRef
    • Tumor Clonality and Resistance Mechanisms in EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Implications for Therapeutic Sequencing
      Shinji Kohsaka, Mark Petronczki, Flavio Solca, Makoto Maemondo
      Future Oncology.2019; 15(6): 637.     CrossRef
    • Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma
      Hee Sang Hwang, Heounjeong Go, Ja-Min Park, Sun Young Yoon, Jae-Lyun Lee, Se Un Jeong, Yong Mee Cho
      Laboratory Investigation.2019; 99(5): 659.     CrossRef
    • PRSS3/Mesotrypsin and kallikrein-related peptidase 5 are associated with poor prognosis and contribute to tumor cell invasion and growth in lung adenocarcinoma
      Honghai Ma, Alexandra Hockla, Christine Mehner, Matt Coban, Niv Papo, Derek C. Radisky, Evette S. Radisky
      Scientific Reports.2019;[Epub]     CrossRef
    • MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells
      Mingqi Wang, Renwen Zhang, Shu Zhang, Rui Xu, Qing Yang
      Gene.2019; 700: 110.     CrossRef
    • Association of cell cycle arrest with anticancer drug-induced epithelial-mesenchymal transition in alveolar epithelial cells
      Masashi Kawami, Risako Harada, Takamichi Ojima, Yohei Yamagami, Ryoko Yumoto, Mikihisa Takano
      Toxicology.2019; 424: 152231.     CrossRef
    • Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids
      Qingmei Ye, Kai Liu, Qun Shen, Qingyue Li, Jinghui Hao, Fangxuan Han, Ren-Wang Jiang
      Frontiers in Oncology.2019;[Epub]     CrossRef
    • BTBD7 Downregulates E-Cadherin and Promotes Epithelial-Mesenchymal Transition in Lung Cancer
      Jie Shu, Lin Wang, Fei Han, Yubin Chen, Shunjun Wang, Fanyan Luo
      BioMed Research International.2019; 2019: 1.     CrossRef
    • Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition
      Fei-Fei FENG, Peng CHENG, Chao SUN, Hui WANG, Wei WANG
      Chinese Journal of Natural Medicines.2019; 17(10): 768.     CrossRef
    • The Evaluation of Glioblastoma Cell Dissociation and Its Influence on Its Behavior
      Veronika Skarkova, Marketa Krupova, Barbora Vitovcova, Adam Skarka, Petra Kasparova, Petr Krupa, Vera Kralova, Emil Rudolf
      International Journal of Molecular Sciences.2019; 20(18): 4630.     CrossRef
    • Bidirectional and Opposite Effects of Naïve Mesenchymal Stem Cells Ontumor Growth and Progression
      Faramarz Rahmatizadeh, Shiva Gholizadeh-Ghaleh Aziz, Khodadad Khodadadi, Maryam Lale Ataei, Esmaeil Ebrahimie, Jafar Soleimani Rad, Maryam Pashaiasl
      Advanced Pharmaceutical Bulletin.2019; 9(4): 539.     CrossRef
    • Estrogen receptors promote NSCLC progression by modulating the membrane receptor signaling network: a systems biology perspective
      Xiujuan Gao, Yue Cai, Zhuo Wang, Wenjuan He, Sisi Cao, Rong Xu, Hui Chen
      Journal of Translational Medicine.2019;[Epub]     CrossRef
    • CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma
      Gargi Maity, Arnab Ghosh, Vijayalaxmi Gupta, Inamul Haque, Sandipto Sarkar, Amlan Das, Kakali Dhar, Sneha Bhavanasi, Sumedha S. Gunewardena, Daniel D. Von Hoff, Sanku Mallik, Suman Kambhampati, Sushanta K. Banerjee, Snigdha Banerjee
      Molecular Cancer Therapeutics.2019; 18(4): 788.     CrossRef
    • Role of Cytomorphology in the Era of Liquid Biopsy
      Eduardo Clery, Pasquale Pisapia, Elena Vigliar, Umberto Malapelle, Claudio Bellevicine, Giancarlo Troncone, Fernando C. Schmitt
      Acta Cytologica.2019; 63(6): 497.     CrossRef
    • TGFβ pathway inhibition in the treatment of non-small cell lung cancer
      Pınar Ö. Eser, Pasi A. Jänne
      Pharmacology & Therapeutics.2018; 184: 112.     CrossRef
    • Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
      Shang-Gin Wu, Jin-Yuan Shih
      Molecular Cancer.2018;[Epub]     CrossRef
    • A bibenzyl from Dendrobium ellipsophyllum induces apoptosis in human lung cancer cells
      Anirut Hlosrichok, Somruethai Sumkhemthong, Boonchoo Sritularak, Pithi Chanvorachote, Chatchai Chaotham
      Journal of Natural Medicines.2018; 72(3): 615.     CrossRef
    • A miRNA-200c/cathepsin L feedback loop determines paclitaxel resistance in human lung cancer A549 cells in vitro through regulating epithelial–mesenchymal transition
      Yi-fan Zhao, Mei-ling Han, Ya-jie Xiong, Long Wang, Yao Fei, Xiao Shen, Ying Zhu, Zhong-qin Liang
      Acta Pharmacologica Sinica.2018; 39(6): 1034.     CrossRef
    • Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors
      Jens C. Hahne, Nicola Valeri
      Frontiers in Oncology.2018;[Epub]     CrossRef
    • Bergamottin Suppresses Metastasis of Lung Cancer Cells through Abrogation of Diverse Oncogenic Signaling Cascades and Epithelial-to-Mesenchymal Transition
      Jeong-Hyeon Ko, Dongwoo Nam, Jae-Young Um, Sang Jung, Gautam Sethi, Kwang Ahn
      Molecules.2018; 23(7): 1601.     CrossRef
    • Lysyl hydroxylases are transcription targets for GATA3 driving lung cancer cell metastasis
      Wei Liu, Ting Zhang, Lixia Guo, Yuanyuan Wang, Yanan Yang
      Scientific Reports.2018;[Epub]     CrossRef
    • FOXC2 promotes epithelial–mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells
      Yuwen He, Hui Xie, Pengjiu Yu, Shunjun Jiang, Li Wei
      Cancer Chemotherapy and Pharmacology.2018; 82(6): 1049.     CrossRef
    • SPARC acts as a mediator of TGF‐β1 in promoting epithelial‐to‐mesenchymal transition in A549 and H1299 lung cancer cells
      Weichao Sun, Jianguo Feng, Qian Yi, Xichao Xu, Ying Chen, Liling Tang
      BioFactors.2018; 44(5): 453.     CrossRef
    • Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
      Tatsuya Nagano, Motoko Tachihara, Yoshihiro Nishimura
      Cells.2018; 7(11): 212.     CrossRef
    • Epigenetic suppression of E-cadherin expression by Snail2 during the metastasis of colorectal cancer
      Yue Hu, Mingrui Dai, Yayuan Zheng, Jiaxin Wu, Bin Yu, Haihong Zhang, Wei Kong, Hui Wu, Xianghui Yu
      Clinical Epigenetics.2018;[Epub]     CrossRef
    • Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance
      Yingjiao Xue, Shenda Hou, Hongbin Ji, Xiangkun Han
      Protein & Cell.2017; 8(3): 178.     CrossRef
    • Benzophenone-3 increases metastasis potential in lung cancer cells via epithelial to mesenchymal transition
      Preeyaporn Plaimee Phiboonchaiyanan, Kesarin Busaranon, Chuanpit Ninsontia, Pithi Chanvorachote
      Cell Biology and Toxicology.2017; 33(3): 251.     CrossRef
    • Molecular mechanisms of therapy resistance in solid tumors: chasing “moving” targets
      Laura J. Tafe
      Virchows Archiv.2017; 471(2): 155.     CrossRef
    • Duchesnea indicaextract suppresses the migration of human lung adenocarcinoma cells by inhibiting epithelial-mesenchymal transition
      Pei-Ni Chen, Shun-Fa Yang, Cheng-Chia Yu, Chin-Yin Lin, Shih-Han Huang, Shu-Chen Chu, Yih-Shou Hsieh
      Environmental Toxicology.2017; 32(8): 2053.     CrossRef
    • Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
      Byoung Soo Kwon, Ji Hyun Park, Woo Sung Kim, Joon Seon Song, Chang-Min Choi, Jin Kyung Rho, Jae Cheol Lee
      Tuberculosis and Respiratory Diseases.2017; 80(2): 187.     CrossRef
    • Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition
      Wei Lou, Yan Chen, Ke-ying Zhu, Huizi Deng, Tianhao Wu, Jun Wang
      Biological & Pharmaceutical Bulletin.2017; 40(8): 1306.     CrossRef
    • Primary patient-derived lung adenocarcinoma cell culture challenges the association of cancer stem cells with epithelial-to-mesenchymal transition
      Verena Tiran, Joerg Lindenmann, Luka Brcic, Ellen Heitzer, Stefanie Stanzer, Nassim Ghaffari Tabrizi-Wizsy, Elvira Stacher, Herbert Stoeger, Helmut H. Popper, Marija Balic, Nadia Dandachi
      Scientific Reports.2017;[Epub]     CrossRef
    • Clusterin modulates transdifferentiation of non-small-cell lung cancer
      Runsen Jin, Xingshi Chen, Dingpei Han, Xiaoying Luo, Hecheng Li
      BMC Cancer.2017;[Epub]     CrossRef
    • Growth Hormone and the Epithelial-to-Mesenchymal Transition
      Alison L Brittain, Reetobrata Basu, Yanrong Qian, John J Kopchick
      The Journal of Clinical Endocrinology & Metabolism.2017; 102(10): 3662.     CrossRef
    • Silencing NUDT21 Attenuates the Mesenchymal Identity of Glioblastoma Cells via the NF-κB Pathway
      Jia-Cheng Lou, Yu-Long Lan, Jin-Xia Gao, Bin-Bin Ma, Ting Yang, Zhong-Bo Yuan, Hong-Qiang Zhang, Ting-Zhun Zhu, Ning Pan, Song Leng, Gui-Jun Song, Bo Zhang
      Frontiers in Molecular Neuroscience.2017;[Epub]     CrossRef
    • Benzo(a)pyrene enhances the EMT-associated migration of lung adenocarcinoma A549 cells by upregulating Twist1
      Xi Chen, Hongbing Peng, Jian Xiao, Anqi Guan, Bin Xie, Bixiu He, Qiong Chen
      Oncology Reports.2017; 38(4): 2141.     CrossRef
    • Gankyrin promotes epithelial-mesenchymal transition and metastasis in NSCLC through forming a closed circle with IL-6/ STAT3 and TGF-β/SMAD3 signaling pathway
      Wu-ping Wang, Ying Sun, Qiang Lu, Jin-bo Zhao, Xue-jiao Wang, Zhao Chen, Yun-feng Ni, Ju-zheng Wang, Yong Han, Zhi-pei Zhang, Xiao-long Yan, Xiao-fei Li
      Oncotarget.2017; 8(4): 5909.     CrossRef
    • Surfactant-based drug delivery systems for treating drug-resistant lung cancer
      Prabhjot Kaur, Tarun Garg, Goutam Rath, R. S. R. Murthy, Amit K. Goyal
      Drug Delivery.2016; 23(3): 717.     CrossRef
    • Moscatilin inhibits epithelial-to-mesenchymal transition and sensitizes anoikis in human lung cancer H460 cells
      Kesarin Busaranon, Preeyaporn Plaimee, Boonchoo Sritularak, Pithi Chanvorachote
      Journal of Natural Medicines.2016; 70(1): 18.     CrossRef
    • SLUG is required for SOX9 stabilization and functions to promote cancer stem cells and metastasis in human lung carcinoma
      S Luanpitpong, J Li, A Manke, K Brundage, E Ellis, S L McLaughlin, P Angsutararux, N Chanthra, M Voronkova, Y C Chen, L Wang, P Chanvorachote, M Pei, S Issaragrisil, Y Rojanasakul
      Oncogene.2016; 35(22): 2824.     CrossRef
    • Endothelial Transdifferentiation of Tumor Cells Triggered by the Twist1‐Jagged1‐KLF4 Axis: Relationship between Cancer Stemness and Angiogenesis
      Hsiao-Fan Chen, Kou-Juey Wu, Silvia Brunelli
      Stem Cells International.2016;[Epub]     CrossRef
    • The attenuation of epithelial to mesenchymal transition and induction of anoikis by gigantol in human lung cancer H460 cells
      Thitita Unahabhokha, Pithi Chanvorachote, Varisa Pongrakhananon
      Tumor Biology.2016; 37(7): 8633.     CrossRef
    • Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner
      Sung-Hak Kim, Ravesanker Ezhilarasan, Emma Phillips, Daniel Gallego-Perez, Amanda Sparks, David Taylor, Katherine Ladner, Takuya Furuta, Hemragul Sabit, Rishi Chhipa, Ju Hwan Cho, Ahmed Mohyeldin, Samuel Beck, Kazuhiko Kurozumi, Toshihiko Kuroiwa, Ryoichi
      Cancer Cell.2016; 29(2): 201.     CrossRef
    • Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells
      Xin Liu, Li-Li Ban, Gang Luo, Zhi-Yao Li, Yun-Feng Li, Yong-Chun Zhou, Xi-Cai Wang, Cong-Guo Jin, Jia-Gui Ye, Ding-Ding Ma, Qing Xie, You-Guang Huang
      Anti-Cancer Drugs.2016; 27(5): 417.     CrossRef
    • ANGPTL4 Correlates with NSCLC Progression and Regulates Epithelial-Mesenchymal Transition via ERK Pathway
      Xiaoming Zhu, Xiaobin Guo, Sen Wu, Li Wei
      Lung.2016; 194(4): 637.     CrossRef
    • Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment
      Yang Ni, Jingwang Bi, Xin Ye, Weijun Fan, Guohua Yu, Xia Yang, Guanghui Huang, Wenhong Li, Jiao Wang, Xiaoying Han, Xiang Ni, Zhigang Wei, Mingyong Han, Aimin Zheng, Min Meng, Guoliang Xue, Liang Zhang, Chao Wan
      Medicine.2016; 95(25): e3998.     CrossRef
    • Effects of RECQ1 helicase silencing on non-small cell lung cancer cells
      Lin Li, Mingyang Gao, Bo Song, Hua Zhang, Yanfu Wang
      Biomedicine & Pharmacotherapy.2016; 83: 1227.     CrossRef
    • Gigantol Inhibits Epithelial to Mesenchymal Process in Human Lung Cancer Cells
      Thitita Unahabhokha, Pithi Chanvorachote, Boonchoo Sritularak, Jutarat Kitsongsermthon, Varisa Pongrakhananon, Yoshiki Mukudai
      Evidence-Based Complementary and Alternative Medicine.2016;[Epub]     CrossRef
    • DUOX1 silencing in lung cancer promotes EMT, cancer stem cell characteristics and invasive properties
      A C Little, D Sham, M Hristova, K Danyal, D E Heppner, R A Bauer, L M Sipsey, A Habibovic, A van der Vliet
      Oncogenesis.2016; 5(10): e261.     CrossRef
    • Long range personalized cancer treatment strategies incorporating evolutionary dynamics
      Chen-Hsiang Yeang, Robert A. Beckman
      Biology Direct.2016;[Epub]     CrossRef
    • Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells
      Mei-ling Han, Yi-fan Zhao, Cai-hong Tan, Ya-jie Xiong, Wen-juan Wang, Feng Wu, Yao Fei, Long Wang, Zhong-qin Liang
      Acta Pharmacologica Sinica.2016; 37(12): 1606.     CrossRef
    • Highly Expressed Integrin-α8 Induces Epithelial to Mesenchymal Transition-Like Features in Multiple Myeloma with Early Relapse
      Jiyeon Ryu, Youngil Koh, Hyejoo Park, Dae Yoon Kim, Dong Chan Kim, Ja Min Byun, Hyun Jung Lee, Sung-Soo Yoon
      Molecules and Cells.2016; 39(12): 898.     CrossRef
    • Gain-of-function p53 mutant with 21-bp deletion confers susceptibility to multidrug resistance in MCF-7 cells
      SHANG-HSUN TSOU, MING-HUNG HOU, LIH-CHING HSU, TZER-MING CHEN, YEN-HUI CHEN
      International Journal of Molecular Medicine.2016; 37(1): 233.     CrossRef
    • Overexpression of PAD4 suppresses drug resistance of NSCLC cell lines to gefitinib through inhibiting Elk1-mediated epithelial-mesenchymal transition
      QIONG DUAN, CUI PANG, NING CHANG, JU ZHANG, WENCHAO LIU
      Oncology Reports.2016; 36(1): 551.     CrossRef
    • Iron induces cancer stem cells and aggressive phenotypes in human lung cancer cells
      Pithi Chanvorachote, Sudjit Luanpitpong
      American Journal of Physiology-Cell Physiology.2016; 310(9): C728.     CrossRef
    • miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer
      Fa-yong Hu, Xiao-nian Cao, Qin-zi Xu, Yu Deng, Sen-yan Lai, Jing Ma, Jun-bo Hu
      Journal of Huazhong University of Science and Technology [Medical Sciences].2016; 36(6): 839.     CrossRef
    • Side population cells from long-term passage non-small cell lung cancer cells display loss of cancer stem cell-like properties and chemoradioresistance
      Hao Gu, Xin-Yu Wu, Rui-Tai Fan, Xin Wang, You-Zhong Guo, Rui Wang
      Oncology Letters.2016; 12(4): 2886.     CrossRef
    • Ubiquilin1 represses migration and epithelial-to-mesenchymal transition of human non-small cell lung cancer cells
      P P Shah, W W Lockwood, K Saurabh, Z Kurlawala, S P Shannon, S Waigel, W Zacharias, L J Beverly
      Oncogene.2015; 34(13): 1709.     CrossRef
    • AEG-1 3′-untranslated region functions as a ceRNA in inducing epithelial–mesenchymal transition of human non-small cell lung cancer by regulating miR-30a activity
      Kunmei Liu, Le Guo, Yongjian Guo, Bo Zhou, Tong Li, Hua Yang, Runting Yin, Tao Xi
      European Journal of Cell Biology.2015; 94(1): 22.     CrossRef
    • SDF-1/CXCR4 signaling up-regulates survivin to regulate human sacral chondrosarcoma cell cycle and epithelial–mesenchymal transition via ERK and PI3K/AKT pathway
      Peng Yang, Gang Wang, Hongjun Huo, Qiang Li, Yan Zhao, Yuanhang Liu
      Medical Oncology.2015;[Epub]     CrossRef
    • Extracellular vesicles in the biology of brain tumour stem cells – Implications for inter-cellular communication, therapy and biomarker development
      Ichiro Nakano, Delphine Garnier, Mutsuko Minata, Janusz Rak
      Seminars in Cell & Developmental Biology.2015; 40: 17.     CrossRef
    • Slug contributes to cancer progression by direct regulation of ERα signaling pathway
      YOUQIANG LI, YANYUAN WU, THOMAS C. ABBATIELLO, WARREN L. WU, JU RI KIM, MARIANNA SARKISSYAN, SUREN SARKISSYAN, SEYUNG S. CHUNG, YAHYA ELSHIMALI, JAYDUTT V. VADGAMA
      International Journal of Oncology.2015; 46(4): 1461.     CrossRef
    • Integrin-Linked Kinase, Snail and Multidrug Resistance Protein 1: Three concordant players in the progression of non-small cell lung cancer
      Dalia M. Abd El-Rehim, Manal I. Abd-Elghany, Maiiada H. Nazmy
      Journal of the Egyptian National Cancer Institute.2015; 27(3): 129.     CrossRef
    • Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
      Vera Hirsh
      BioDrugs.2015; 29(3): 167.     CrossRef
    • Overview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial Fluid
      Gianfranco Baronzio, Gurdev Parmar, Miriam Baronzio
      Frontiers in Oncology.2015;[Epub]     CrossRef
    • Loss of FOXO1 promotes gastric tumour growth and metastasis through upregulation of human epidermal growth factor receptor 2/neu expression
      Young San Ko, Sung Jin Cho, Jinju Park, Younghoon Kim, Yong Joon Choi, Jung-Soo Pyo, Bo Gun Jang, Jong-Wan Park, Woo Ho Kim, Byung Lan Lee
      British Journal of Cancer.2015; 113(8): 1186.     CrossRef
    • Epigallocatechin-3-gallate inhibits nicotine-induced migration and invasion by the suppression of angiogenesis and epithelial-mesenchymal transition in non-small cell lung cancer cells
      JINGLI SHI, FEI LIU, WENZHANG ZHANG, XIN LIU, BIHUA LIN, XUDONG TANG
      Oncology Reports.2015; 33(6): 2972.     CrossRef
    • Aberrant CXCR4 and β-catenin expression in osteosarcoma correlates with patient survival
      YAO LU, GUO-FENG GUAN, JIE CHEN, BIN HU, CONG SUN, QIONG MA, YAN-HUA WEN, XIU-CHUN QIU, YONG ZHOU
      Oncology Letters.2015; 10(4): 2123.     CrossRef
    • Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma
      Kian Ngiap Chua, Li Ren Kong, Wen Jing Sim, Hsien Chun Ng, Weijie Richard Ong, Jean Paul Thiery, Hung Huynh, Boon Cher Goh
      Oncotarget.2015; 6(30): 29991.     CrossRef
    • Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibition
      Roberto Gomez-Casal, Michael W. Epperly, Hong Wang, David A. Proia, Joel S. Greenberger, Vera Levina
      Oncotarget.2015; 6(42): 44306.     CrossRef
    • Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment
      Hye-Ryoun Kim, Jae Chol Lee, Young-Chul Kim, Kyu-Sik Kim, In-Jae Oh, Sung Yong Lee, Tae Won Jang, Min Ki Lee, Kyeong-Cheol Shin, Gwan Ho Lee, Jeong-Seon Ryu, Seung Hoon Jang, Ji Woong Son, Jeong Eun Lee, Sun Young Kim, Hee Joung Kim, Kye Young Lee
      Lung Cancer.2014; 83(2): 252.     CrossRef
    • GPI/AMF inhibition blocks the development of the metastatic phenotype of mature multi-cellular tumor spheroids
      Juan Carlos Gallardo-Pérez, Nadia Alejandra Rivero-Segura, Alvaro Marín-Hernández, Rafael Moreno-Sánchez, Sara Rodríguez-Enríquez
      Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.2014; 1843(6): 1043.     CrossRef
    • Expression of HMGA2 in bladder cancer and its association with epithelial‐to‐mesenchymal transition
      X. Ding, Y. Wang, X. Ma, H. Guo, X. Yan, Q. Chi, J. Li, Y. Hou, C. Wang
      Cell Proliferation.2014; 47(2): 146.     CrossRef
    • Vimentin silencing effect on invasive and migration characteristics of doxorubicin resistant MCF-7 cells
      Okan Tezcan, Ufuk Gündüz
      Biomedicine & Pharmacotherapy.2014; 68(3): 357.     CrossRef
    • Molecular characterization of scant lung tumor cells using iron-oxide nanoparticles and micro-nuclear magnetic resonance
      Arezou A. Ghazani, Melina Pectasides, Amita Sharma, Cesar M. Castro, Mari Mino-Kenudson, Hakho Lee, Jo-Anne O. Shepard, Ralph Weissleder
      Nanomedicine: Nanotechnology, Biology and Medicine.2014; 10(3): 661.     CrossRef
    • Triclosan Potentiates Epithelial-To-Mesenchymal Transition in Anoikis-Resistant Human Lung Cancer Cells
      Thidarat Winitthana, Somsong Lawanprasert, Pithi Chanvorachote, Aamir Ahmad
      PLoS ONE.2014; 9(10): e110851.     CrossRef
    • Rubus idaeus L Inhibits Invasion Potential of Human A549 Lung Cancer Cells by Suppression Epithelial-to-Mesenchymal Transition and Akt Pathway In Vitro and Reduces Tumor Growth In Vivo
      Shu-Chen Chu, Yih-Shou Hsieh, Li-Sung Hsu, Kuo-Shuen Chen, Chien-Cheng Chiang, Pei-Ni Chen
      Integrative Cancer Therapies.2014; 13(3): 259.     CrossRef
    • The inhibitory effect of anthocyanins on Akt on invasion and epithelial-mesenchymal transition is not associated with the anti-EGFR effect of the anthocyanins
      JING NAN LU, WON SUP LEE, MIN JEONG KIM, JEONG WON YUN, JI HYUN JUNG, SANG MI YI, JAE-HOON JEONG, HYE JUNG KIM, YUNG HYUN CHOI, GON-SUP KIM, CHUNG HO RYU, SUNG CHUL SHIN
      International Journal of Oncology.2014; 44(5): 1756.     CrossRef
    • Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer
      Tim N. Beck, Adaeze J. Chikwem, Nehal R. Solanki, Erica A. Golemis
      Physiological Genomics.2014; 46(19): 699.     CrossRef
    • Overexpression of c-Met increases the tumor invasion of human prostate LNCaP cancer cells in vitro and in vivo
      YILI HAN, YONG LUO, JIAHUI ZHAO, MINGCHUAN LI, YONGGUANG JIANG
      Oncology Letters.2014; 8(4): 1618.     CrossRef
    • YAP-Induced Resistance of Cancer Cells to Antitubulin Drugs Is Modulated by a Hippo-Independent Pathway
      Yulei Zhao, Prem Khanal, Paul Savage, Yi-Min She, Terry D. Cyr, Xiaolong Yang
      Cancer Research.2014; 74(16): 4493.     CrossRef
    • Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis
      Jie Xu, Cai-feng Yue, Wei-hua Zhou, Yuan-min Qian, Yan Zhang, Shao-wu Wang, An-wen Liu, Quentin Liu
      Journal of Translational Medicine.2014;[Epub]     CrossRef
    • Ezrin promotes invasion and migration of the MG63 osteosarcoma cell
      Jian Zhang, Jianhong Zuo, Mingsheng Lei, Song Wu, Xiaofang Zang, Chaoyue Zhang
      Chinese Medical Journal.2014; 127(10): 1954.     CrossRef
    • Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
      D Gonzalez de Castro, P A Clarke, B Al-Lazikani, P Workman
      Clinical Pharmacology & Therapeutics.2013; 93(3): 252.     CrossRef
    • Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
      John R. Goffin, Kevin Zbuk
      Clinical Therapeutics.2013; 35(9): 1282.     CrossRef
    • Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo
      Sílvia Cufí, Rosa Bonavia, Alejandro Vazquez-Martin, Cristina Oliveras-Ferraros, Bruna Corominas-Faja, Elisabet Cuyàs, Begoña Martin-Castillo, Enrique Barrajón-Catalán, Joana Visa, Antonio Segura-Carretero, Jorge Joven, Joaquim Bosch-Barrera, Vicente Mico
      Scientific Reports.2013;[Epub]     CrossRef
    • Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells
      Sílvia Cufí, Rosa Bonavia, Alejandro Vazquez-Martin, Bruna Corominas-Faja, Cristina Oliveras-Ferraros, Elisabet Cuyàs, Begoña Martin-Castillo, Enrique Barrajón-Catalán, Joana Visa, Antonio Segura-Carretero, Joaquim Bosch-Barrera, Jorge Joven, Vicente Mico
      Food and Chemical Toxicology.2013; 60: 360.     CrossRef
    • Rubus idaeus L. reverses epithelial-to-mesenchymal transition and suppresses cell invasion and protease activities by targeting ERK1/2 and FAK pathways in human lung cancer cells
      Yih-Shou Hsieh, Shu-Chen Chu, Li-Sung Hsu, Kuo-Shuen Chen, Ming-Tsung Lai, Chia-Heng Yeh, Pei-Ni Chen
      Food and Chemical Toxicology.2013; 62: 908.     CrossRef
    • Alteration of the E-cadherin/β-Catenin Complex Predicts Poor Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment
      Seol Bong Yoo, Yu Jung Kim, Hyojin Kim, Yan Jin, Ping-Li Sun, Sanghoon Jheon, Jong Seok Lee, Jin-Haeng Chung
      Annals of Surgical Oncology.2013; 20(S3): 545.     CrossRef
    • Lung cancer stem cells: a biological and clinical perspective
      Ana Koren, Helena Motaln, Tanja Cufer
      Cellular Oncology.2013; 36(4): 265.     CrossRef
    • Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology
      Paul Workman, Bissan Al-Lazikani, Paul A Clarke
      Current Opinion in Pharmacology.2013; 13(4): 486.     CrossRef
    • Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
      Jae Cheol Lee, Seung Hun Jang, Kye Young Lee, Young-Chul Kim
      Cancer Research and Treatment.2013; 45(2): 79.     CrossRef
    • Stem cell-like ALDHbrightcellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin
      BRUNA COROMINAS-FAJA, Cristina Oliveras-Ferraros, ELISABET CUYÀS, Antonio Segura-Carretero, Jorge Joven, Begoña Martin-Castillo, ENRIQUE BARRAJÓN-CATALÁN, Vicente Micol, Joaquim Bosch-Barrera, JAVIERABEL MENENDEZ MENENDEZ
      Cell Cycle.2013; 12(21): 3390.     CrossRef
    • Menadione (Vitamin K3) Induces Apoptosis of Human Oral Cancer Cells and Reduces their Metastatic Potential by Modulating the Expression of Epithelial to Mesenchymal Transition Markers and Inhibiting Migration
      Shruthy Suresh, Dinesh Raghu, Devarajan Karunagaran
      Asian Pacific Journal of Cancer Prevention.2013; 14(9): 5461.     CrossRef
    • Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
      Silvia La Monica, Cristina Caffarra, Francesca Saccani, Elena Galvani, Maricla Galetti, Claudia Fumarola, Mara Bonelli, Andrea Cavazzoni, Daniele Cretella, Rita Sirangelo, Rita Gatti, Marcello Tiseo, Andrea Ardizzoni, Elisa Giovannetti, Pier Giorgio Petro
      PLoS ONE.2013; 8(10): e78656.     CrossRef
    • Analysis of Flora Distribution and Drug Resistance in Sputum Culture from Patients with Lung Cancer
      Feng Hao, Rui Ze Ma, Xue Yan Wang, Hui Jing Xu, Fang Fang, Li Zhang, Hui Zheng, Yu Xuan Zang, Yan Li
      Advanced Materials Research.2013; 641-642: 625.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite
      CITE
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Epithelial Mesenchymal Transition in Drug Resistance and Metastasis of Lung Cancer
      Cancer Res Treat. 2012;44(3):151-156.   Published online September 30, 2012
      DOI: https://doi.org/10.4143/crt.2012.44.3.151
      Close
    • XML DownloadXML Download
    Epithelial Mesenchymal Transition in Drug Resistance and Metastasis of Lung Cancer
    Epithelial Mesenchymal Transition in Drug Resistance and Metastasis of Lung Cancer
    Cancer Res Treat : Cancer Research and Treatment
    © Korean Cancer Association.
    Close layer
    TOP